Title 43, Chapter 30, Section 1
( 43-30-1)
As used in this chapter, the term: (1) "Board" means the State Board of Optometry. (2)(A) "Optometry" means the art and science of visual care and
is declared to be a learned profession. The practice of
optometry consists of the diagnosis and interpretation of the
visual behavior of the human organism by the employment of any
means other than surgery. The practice of optometry further
consists of the correction of visual anomalies through the
prescribing, employment, and use of lenses, prisms, frames,
mountings, contact lenses, orthoptic exercises, and visual
training, light frequencies, and any other means or methods for
the relief, correction, or remedy of any insufficiencies or
abnormal conditions of the human visual organism, other than
surgery. Optometrists are prohibited from using nondiagnostic
lasers. Nothing in this chapter shall prohibit the use,
administration, or prescription of pharmaceutical agents for
diagnostic purposes and treatment of ocular disease in the
practice of optometry by optometrists who have received
pharmacological training and certification from a properly
accredited institution of higher learning and who are certified
by the board to use pharmaceutical agents for diagnostic and
treatment purposes. Only a doctor of optometry who: (i) Is already certified for using pharmaceutical agents for
diagnostic purposes; (ii) Has passed or passes an examination approved by the board
which tests knowledge of pharmacology for treatment and
management of ocular diseases; (iii) Is certified in coronary pulmonary resuscitation (CPR);
and (iv) Maintains at least $1 million in malpractice insurance
coverage shall be certified to use pharmaceutical agents for treatment
purposes. (B) The board shall establish by rule a list, which may be
modified from time to time, of pharmaceutical agents which
optometrists shall be allowed to use for treatment purposes. (C) A doctor of optometry shall not administer any
pharmaceutical agent by injection. (D) Pharmaceutical agents which are used by a doctor of
optometry for treatment purposes and administered orally may
only be: (i) Nonnarcotic oral analgesics and Schedule III or Schedule
IV controlled substances which are oral analgesics; (ii) Used for ocular pain; and (iii) Used for no more than 72 hours without consultation with
the patient's physician. (E) Pharmaceutical agents which are used by a doctor of
optometry for treatment purposes and administered topically
shall be subject to the following conditions only when used for
the treatment of glaucoma: (i) If the pharmaceutical agent is a beta blocker, an
optometrist certified to use pharmaceutical agents for
treatment purposes must take a complete case history and
determine whether the patient has had a physical examination
within the past year. If the patient has not had such a
physical examination or if the patient has any history of
congestive heart failure, bradycardia, heart block, asthma, or
chronic obstructive pulmonary disease, that patient must be
referred to a person licensed under Chapter 34 of this title
for examination prior to initiating beta blocker therapy; (ii) If the glaucoma patient does not respond to the topically
administered pharmaceutical agents after 60 days of treatment,
that patient must be referred to an ophthalmologist; and (iii) If the patient is diagnosed as having closed angle
glaucoma, the patient shall be immediately referred to an
ophthalmologist. (F) Doctors of optometry using pharmaceutical agents for treatment purposes shall be held to the same standard of care imposed by Code Section 51-1-27 as would be applied to a physician licensed under Chapter 34 of this title performing similar acts. (G) Any doctor of optometry who uses a pharmaceutical agent,
except under the conditions specified therefor by this chapter
and any other law, shall be guilty of a misdemeanor unless a
greater penalty is otherwise provided by law. (H) Nothing in this chapter shall be construed to allow a doctor
of optometry to dispense pharmaceutical agents to patients. |